Walter Berger, Univ.-Prof. Mag. Dr.
Coordinator of Research Focus "Applied and Experimental Oncology"
Group Leader
E-Mail: walter.berger [at] meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57555
Fax: +43 (0)1 40160 - 957555
Research Focus
By far the majority of cancer deaths are caused by disseminated solid tumors exhibiting therapy resistance. Consequently, our translational and multidisciplinary cooperation projects focus on the development of novel therapeutic strategies in highly therapy-refractory cancers including lung cancer, mesothelioma, brain tumors and melanoma.
Thereby we aim on the:
- identification of genetic and molecular factors driving solid tumor aggressiveness and therapy resistance thus representing potential targets for therapeutic interventions;
- development of novel anticancer agents and drug combinations allowing to avoid therapy failure and resistance development.
Financial support: Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung, FWF): P19920, P17630, L212, L568, P22072
GENAU, (PLACEBO with CEMM), FFG, EU/COST (CM1105-MC), OEAD with Ukraine (National Academy of Science) and Hungary (Koranyi Institut), Herzfelder'sche Familienstiftung, Jubiläumsfonds der Österreichischen Nationalbank, Hochschuljubiläumsstiftung der Stadt Wien, Initiative Krebsforschung, Fonds des Bürgermeisters der Bundeshauptstadt Wien, Oberösterrreichische Krebshilfe, Pharmaceutical Companies
Videos
Selected Publications
Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup.
Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, Stockhammer P, Lötsch-Gojo D, Gojo J, Gabler L, Spiegl-Kreinecker S, Doeme B, Steindl A, Klikovits T, Hoda MA, Jakopovic M, Samarzija M, Mohorcic K, Kern I, Kiesel B, Brcic L, Oberndorfer F, Müllauer L, Klepetko W, Schmidt WM, Kumar R, Hegedus B, Berger W.
Clin Cancer Res. 2020 Jul 15;26(14):3819-3830. doi: 10.1158/1078-0432.CCR-19-3573.
Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
Englinger B, Laemmerer A, Moser P, Kallus S, Röhrl C, Pirker C, Baier D, Mohr T, Niederstaetter L, Meier-Menches SM, Gerner C, Gabler L, Gojo J, Timelthaler G, Senkiv J, Jäger W, Kowol CR, Heffeter P, Berger W.
Int J Cancer. 2020 Sep 15;147(6):1680-1693. doi: 10.1002/ijc.32924.
Single-cell RNA-seq reveals cellular hierarchies and impaired developmental trajectories in pediatric ependymoma.
Gojo J, Englinger B, Jiang L, et al., Berger W, Kool M, Filbin MG.
Cancer Cell. 2020 Jul 13;38(1):44-59.e9. doi: 10.1016/j.ccell.2020.06.004.
Subcellular duplex DNA and G-quadruplex interaction profiling of a hexagonal Pt(II) metallacycle.
Domarco O, Kieler C, Pirker C, Dinhof C, Englinger B, Reisecker JM, Timelthaler G, García MD, Peinador C, Keppler BK, Berger W, Terenzi A.
Angew Chem Int Ed Engl. 2019 Jun 11;58(24):8007-8012. doi: 10.1002/anie.201900934.
Metal drugs and the anticancer immune response.
Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W.
Chem Rev. 2019 Jan 23;119(2):1519-1624. doi: 10.1021/acs.chemrev.8b00396.